Holen Sie sich die Stockscreener-App
11.25
0.00%
0.00
Vorhandelsmarkt:
11.35
0.10
+0.89%
Schlusskurs vom Vortag:
$11.25
Offen:
$11.23
24-Stunden-Volumen:
640.75K
Relative Volume:
0.72
Marktkapitalisierung:
$860.06M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-3.8927
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
-7.41%
1M Leistung:
-2.09%
6M Leistung:
-42.84%
1J Leistung:
-49.10%
1-Tages-Spanne:
$11.13
$11.40
1-Wochen-Bereich:
$11.12
$12.60
52-Wochen-Spanne:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.25 | 928.86M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
Nurix Therapeutics Inc. Stock Analysis and ForecastJaw-dropping returns - printweek.in
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
Is Nurix Therapeutics Inc. a good long term investmentSuperior stock selection - jammulinksnews.com
Massachusetts Financial Services Co. MA Sells 24,398 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Hussman Strategic Advisors Inc. Invests $499,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
What drives Nurix Therapeutics Inc. stock priceExceptional profit velocity - jammulinksnews.com
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress By Investing.com - Investing.com South Africa
Nurix Therapeutics’ SWOT analysis: biotech stock’s pivotal trials and pipeline progress - Investing.com Australia
When (NRIX) Moves Investors should Listen - news.stocktradersdaily.com
Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright - Yahoo Finance
NRIX: Morgan Stanley Lowers Price Target for Nurix Therapeutics - GuruFocus
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts - Benzinga
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $34.00 at HC Wainwright - MarketBeat
H.C. Wainwright Adjusts Price Target for Nurix Therapeutics (NRI - GuruFocus
Navigating Nurix Therapeutics' Early-Stage Biotech Landscape: A Strategic SWOT Analysis - AInvest
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $30.00 by Analysts at Oppenheimer - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat
Nurix Therapeutics: The BTK Disruptor With Undervalued Upside Potential - AInvest
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics' (NRIX) "Overweight" Rating Reaffirmed at Stephens - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 7.8% After Earnings Beat - MarketBeat
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Piper Sandler Keeps Their Buy Rating on Nurix Therapeutics (NRIX) - The Globe and Mail
Nurix Therapeutics (NRIX) Stock Target Price Lowered by UBS Anal - GuruFocus
UBS Group Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $26.00 - MarketBeat
Mixed Moves In Health And Biotech Funds - Finimize
Oppenheimer Adjusts Price Target on Nurix Therapeutics to $30 From $32, Maintains Outperform Rating - MarketScreener
Stephens & Co. Reiterates Overweight Rating for Nurix Therapeuti - GuruFocus
UBS Adjusts Price Target on Nurix Therapeutics to $26 From $30, Keeps Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX) | - GuruFocus
Nurix Therapeutics (NRIX) Target Price Adjusted by UBS | NRIX St - GuruFocus
Nurix Therapeutics: Strategic Catalysts and Financial Strength Positioning for Long-Term Growth - AInvest
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket - MarketScreener
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):